Eli Lilly's Mirikizumab Shows Long-Term Sustained Efficacy, Safety For Ulcerative Colitis And Crohn's Disease

On Monday, Eli Lilly And Co (NYSE:LLY) announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases (IBD).

The studies showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis and Crohn’s disease.

Data from the two trials, LUCENT-3 in moderately to severely active ulcerative colitis and VIVID-2 in moderately to severely active Crohn’s disease, will be presented at the American College of Gastroenterology Annual Meeting.

Mirikizumab is approved as Omvoh in the U.S. for moderately to severely active ulcerative colitis in adults and is under FDA review for moderately to severely active Crohn’s disease.

Also Read: Eli Lilly’s Newly FDA-Approved Eczema ...